Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Taps Pfizer Exec To Run New Global Development HQ

This article was originally published in PharmAsia News

Executive Summary

Long-time Pfizer exec Steven Ryder will become president of Astellas Pharma's new headquarters for global development in Deerfield, Ill., effective April 1, the Tokyo-based company announced March 4

You may also be interested in...



U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen

FDA has deemed FibroGen's response to a clinical hold on two oral anemia therapy candidates complete, allowing Phase II trials of the compounds to resume, FibroGen's development partner, Astellas Pharma, announced April 2

U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen

FDA has deemed FibroGen's response to a clinical hold on two oral anemia therapy candidates complete, allowing Phase II trials of the compounds to resume, FibroGen's development partner, Astellas Pharma, announced April 2

Analysts View Astellas’ Pick Of Former Pfizer Exec To Head Global Development As Nod To Daiichi Sankyo's Success

TOKYO - Astellas Pharma's decision to move its global development headquarters to Illinois may be a reflection of how other major Japanese pharmas see Daiichi Sankyo's position in the market, a Japanese analyst says

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel